Clinical Trial

Clinical Performance of XPEO-E Liner in SERF Dual-mobility Cups

Study acronym: 2024-01-XPEO-E
Recruiting
View on ClinicalTrials.gov →
Summary
XPEO-E liner is CE marked under MDD 93/42/CEE by equivalency with CI E liner. No pertaining data on XPEO-E liner is yet available. However, clinical evaluation concludes on a reaching of performance and safety and compliance with essential requirements. This study intends to collect data on XPEO-E in order to allow a transit to MDR 2017/745 (EU). XPEO-E liner is intended to be used with NOVAE cups and SERF femoral heads and Stems. XPEO-E liner will be used according to their CE marking. These devices are intended for hip replacements with the aim of improving quality of life and reducing pain by replacing a damaged joint. The follow-up visits are established according to the current practice. Additional procedure will only consist on questionnaires that will be filled by the patient and/or the surgeons.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-04-01; most recent amendment 2026-04-09.
Status change: Not Yet Recruiting → Recruiting 2026-04-09
Trial Details
NCT Number NCT06917365
Lead Sponsor Societe dEtude, de Recherche et de Fabrication
Conditions Total Hip Arthroplasty (THA)
Enrollment 500 participants
Start Date 2025-10-27
Primary Completion 2032-03-31 (estimated)
Study Completion 2032-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-13